Alpha Tau to Present Pooled Pancreatic Cancer Data from Three Alpha DaRT Studies at ASCO 2026

On April 27, 2026, Alpha Tau Medical Ltd. announced that a pooled analysis of safety and efficacy data from three clinical studies evaluating Alpha DaRT® in advanced pancreatic cancer has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The analysis combines data from 58 patients treated with endoscopic ultrasound (EUS)-guided intratumoral Alpha DaRT at centers in Canada and Israel. The studies focused on patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). The company highlighted that the EUS-guided approach has proven technically feasible and integrates well into clinical workflows. While full data will be published on the ASCO website on May 21, 2026, the company indicated that the results provide a strong foundation of clinical evidence for its ongoing pancreatic cancer program. This includes the U.S. multicenter IMPACT trial (newly diagnosed unresectable pancreatic cancer) and the ACAPELLA trial in France (locally advanced pancreatic cancer). Management views the ASCO acceptance as a significant validation of their global clinical pipeline for one of oncology's highest unmet needs.